Business

PerkinElmer has successfully completed the divestiture of its Applied, Food and Enterprise Services businesses to New Mountain Capital. The resulting new Life Sciences and Diagnostics business will share the PerkinElmer name until a new name, brand and ticker symbol is unveiled in Q2 2023 pending shareholder approval. “Today marks the culmination of the hard work […]

Craig Caceci, Managing Director at Terebellum, offers guidance to pharmaceutical companies that are in the position to take their drugs to market.  In today’s competitive environment, a winning, fail-safe drug launch strategy is more important than ever, especially with increased NHS and private payer influence, steep standards for coverage and ongoing issues such as safety, […]

Kristina Tatiossian, PhD, founder of Arkitekt Agency, looks at how biotech companies are currently using social media and provides a five-step guide for how to make the most of this ubiquitous marketing tool. Biotechnology organisations can leverage social media for a variety of purposes, from boosting awareness and increasing engagement, to connecting with stakeholders and […]

DDW Editor Reece Armstrong takes a look at the pharmaceutical research and development market in 2023 and asks key opinion leaders what challenges and trends will emerge throughout the year.   The Market After over two years of the Covid-19 pandemic, 2022 year was somewhat of a return to normal for both the world at […]

WuXi STA, a subsidiary of WuXi AppTec, has received scores of 60+ with a Silver rating from EcoVadis, a provider of business sustainability ratings, for its three sites in China.  The scores were received for active pharmaceutical ingredients (API) R&D and manufacturing from the Changzhou site, and for formulation development and manufacturing from the Shanghai […]

GSK has announced strong quarterly results, reporting sales of £7.8 billion and growth in various sectors of the business.   Overall, the company’s adjusted operating profit for the third quarter came in at £2.6 billion, a 17% increase compared to the same period last year and reflecting a 4% year-on-growth at CER.   The quarterly results are […]

Clinical-stage company Respira Technologies has appointed a new Chief Executive Officer (CEO) to the company.  Brian Quigley will take over as CEO after working as Respira’s Chief Operating Officer (COO) for the past two years.   Quigley previously worked at Altria Group for 16 years where he spent seven years as President & CEO at Altria’s […]

Artificial intelligence (AI) company Atomwise has signed an exclusive research collaboration with Sanofi to use its AtomNet platform for computational discovery and research of up to five drug targets.  The agreement will see Atomwise receive $20 million from Sanofi to identify, synthesise, and advance lead compounds for up to five targets, which will be exclusive to […]

Clinical-stage drug discovery company Ryvu Therapeutics has received €22 million from the European Investment Bank (EIB) to help it advance its portfolio of cancer treatments.   The funding, which is being provided under the EIB’s venture debt instrument, will help Ryvu finance its development pipeline of new cancer treatments from discovery through to clinical trials. Ryvu’s […]

News round-up by DDW’s Reece Armstrong for 8-12 August  New insights into melanoma, a company transition into life sciences and a Lyme disease vaccine are some of the stories in this week’s news round-up. Pfizer launches Phase III trial for Lyme disease vaccine    Pfizer has launched a Phase III clinical trial of a vaccine to […]